

---

# Communications

---

## Myopathic Presentation of Thyroiditis

James L. Fletcher, Jr, MD  
Augusta, Georgia

"Few present-day physicians, aside from endocrinologists, know that hypothyroidism may cause profound myopathy," wrote Fessel in 1968.<sup>1</sup> Even fewer physicians would appreciate a connection between thyroiditis and myopathy. A case of this association is presented in an attempt to alert primary care physicians to this potential presentation of a treatable disorder.

### Case Report

A 30-year-old male tombstone carver, previously well, presented with a complaint of weakness of two weeks' duration. The weakness involved the thighs, calves, and upper arms, but not the hands or feet. He also noted that he had intermittent cramping of the calves and that his arms and legs sometimes "went to sleep." There was no previous history of these symptoms. He denied weight loss, fever, neck pain, recent acute illness, or anorexia.

Past medical history revealed no significant illness or surgery. He took no medications chronically. He smoked about ten cigarettes daily and drank an occasional beer, but denied problem drinking. His family history was significant for asthma and an unknown neuromuscular disorder that confined his sister to a wheelchair (there were no other family members so affected). There was no family history of thyroid disease. In his work he was exposed often to a lacquer thinner, but there was no history of exposure to lead or other heavy metals.

Physical examination revealed a muscular individual with a weight of 199 lb, blood pressure of 102/78 mmHg, and a regular pulse of 60 beats/min. There was no palpable goiter or any neck tenderness. Skin and hair appeared normal. Deep tendon reflexes were 2+ at the knees, 2+ at the biceps, 3+ at the triceps; relaxation phase appeared normal. Pinprick sensation was everywhere intact. Testing of multiple muscle groups revealed good strength, graded 5/5, without demonstrable weakness of proximal musculature; there was no peripheral edema or notable muscle tenderness to palpation.

Initial laboratory studies revealed a normal urinalysis, complete blood count, and sedimentation rate. A chemical profile showed an elevated creatine phosphokinase (CPK) of 2,805 U/mL (nor-

---

From the Department of Family Practice, Medical College of Georgia, Augusta, Georgia. Requests for reprints should be addressed to Dr. James L. Fletcher, Jr, Department of Family Practice, Medical College of Georgia, 1120 15th Street, Augusta, GA 30912.

mal, 0 to 140 U/mL); repeated the following day, it was 2,942 U/mL. Five other elevated items were noted: SGPT 60 U/mL (normal, 6 to 37 U/mL), SGOT 84 U/mL (normal, 10 to 30 U/mL), lactic dehydrogenase (LDH) 356 U/mL (normal 109 to 193 U/mL), cholesterol 340 mg/dL (normal, 115 to 252 mg/dL), and creatinine 1.62 mg/dL (normal 0.7 to 1.5 mg/dL).

A diagnosis of myopathy, type and cause unspecified, was made; a symptomatic medicine was begun and bed rest recommended. Thyroid function studies were obtained, revealing a depressed  $T_4$  of 0.6  $\mu\text{g/dL}$  (normal, 4.5 to 12  $\mu\text{g/dL}$ ) and  $T_3$  by radioimmunoassay of 35 ng/dL (normal, 80 to 220 ng/dL); thyroid stimulating hormone (TSH) was greater than 40  $\mu\text{U/mL}$  (normal 0 to 10  $\mu\text{U/mL}$ ). The patient was begun on L-thyroxine, and thyroid antibody studies were obtained. Antimicrosomal antibody was not found; however, antithyroglobulin antibody was very significantly positive in a titer of 1:10,485,760. A radioactive iodine scan prior to treatment showed uptake at 24 hours to be less than 2 percent.

Two weeks later the patient returned, taking L-thyroxine and feeling better. His CPK level was 1,340 U/mL and his weight 198 lb. His thyroid gland was felt to be about 3 cm across (total diameter), not unusually firm, and without discrete masses, nodules, or tenderness.

He was then lost to follow-up until about five months later, when, on return, his weight was 194 lb. His thyroid gland was again not enlarged and was without discrete masses. Serum studies at this time revealed a CPK of 170 U/mL, normal cholesterol (224 mg/dL),  $T_4$  of 4.7  $\mu\text{g/dL}$ ,  $T_3$  resin of 28.9 percent (normal, 22 to 34 percent),  $T_7$  of 1.4 (normal, 1.3 to 3.4), but again, a TSH of greater than 40  $\mu\text{U/mL}$ . He avowed taking his medicine faithfully. His dose of L-thyroxine was increased slightly. He was then lost to further follow-up.

## Discussion

Primary hypothyroidism (ie, not secondary to pituitary dysfunction) is a not uncommon diagnosis for the primary care physician. Thyroiditis is

likewise not uncommon, whether the patient presents as euthyroid or in a dysfunctional hormonal state. The provocative feature of the case above is the association of the triad of thyroiditis, hypothyroidism, and myopathy. As a presentation, myopathy usually leads one to consider primary muscular or neuromuscular disorders, but since the late 1800s there has been awareness of a relationship between hypothyroidism and myopathy, with numerous reports from the first half of this century documenting this connection.<sup>1</sup>

During a two-year period, Fessel<sup>1</sup> discovered that 5.6 percent of individuals seen in a community hospital setting for acquired myopathic disorders had hypothyroidism as a presumed cause; furthermore, muscular symptoms were the first to be observed in these particular cases. Pain was not usually a prominent feature, and muscular symptoms responded to therapy with thyroid hormone. He felt that prevalence of muscular disorder with hypothyroidism was "common" and outlined two basic types: (1) hypertrophy with or without myotonia, and (2) atrophy.

In the clinical laboratory, the CPK level has been noted as a useful marker of hypothyroid myopathy. Graig and Smith<sup>2</sup> studied euthyroid controls and hyperthyroid and hypothyroid subjects; they found excellent correlation between the level of CPK activity and thyroid dysfunction. The relationship between serum enzyme levels and thyroid activity was found to be inverse, and serial studies reflected response to appropriate therapy.

Histologic studies have also been performed. Determined by electron microscopy, muscle tissue from patients with hypothyroidism shows mitochondrial changes, excessive glycogen deposits, and various abnormal subsarcolemmal deposits.<sup>3</sup> The mechanism of subcellular changes remains speculative.

Etiology of thyroid hypofunction is usually not mentioned in the studies cited, but thyroiditis (specifically, autoimmune, or Hashimoto's thyroiditis) is a well-documented cause of hypothyroidism.<sup>4</sup> Yet, a myopathic presentation would not necessarily be quickly associated with thyroiditis, and though an association with myasthenia gravis has been described with respect to autoimmune thyroiditis, myopathy (in a more general sense) is


Continued on page 1020

# VERMOX<sup>®</sup> CHEWABLE TABLETS

(mebendazole)

## MYOPATHY IN THYROIDITIS

Continued from page 1018



**DESCRIPTION** VERMOX (mebendazole) is methyl 5-benzoylbenzimidazole-2-carbamate.

**ACTIONS** VERMOX exerts its anthelmintic effect by blocking glucose uptake by the susceptible helminths, thereby depleting the energy level until it becomes inadequate for survival. In man, approximately 2% of administered mebendazole is excreted in urine as unchanged drug or a primary metabolite. Following administration of 100 mg of mebendazole twice daily for three consecutive days, plasma levels of mebendazole and its primary metabolite, the 2-amine, never exceeded 0.03 µg/ml and 0.09 µg/ml, respectively.

**INDICATIONS** VERMOX is indicated for the treatment of *Trichuris trichiura* (whipworm), *Enterobius vermicularis* (pinworm), *Ascaris lumbricoides* (common roundworm), *Ancylostoma duodenale* (common hookworm), *Necator americanus* (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as pre-existing diarrhea and gastrointestinal transit time, degree of infection and helminth strains. Efficacy rates derived from various studies are shown in the table below:

	Whipworm	Common Roundworm	Hookworm	Pinworm
<b>cure rates</b>				
mean	68%	98%	96%	95%
(range)	(61-75%)	(91-100%)	—	(90-100%)
<b>egg reduction</b>				
mean	93%	99.7%	99.9%	—
(range)	(70-99%)	(99.5%-100%)	—	—

**CONTRAINDICATIONS** VERMOX is contraindicated in pregnant women (see Pregnancy Precautions) and in persons who have shown hypersensitivity to the drug.

**PRECAUTIONS PREGNANCY:** VERMOX has shown embryotoxic and teratogenic activity in pregnant rats at single oral doses as low as 10 mg/kg. Since VERMOX may have a risk of producing fetal damage if administered during pregnancy, it is contraindicated in pregnant women.

**PEDIATRIC USE:** The drug has not been extensively studied in children under two years; therefore, in the treatment of children under two years the relative benefit/risk should be considered.

**ADVERSE REACTIONS** Transient symptoms of abdominal pain and diarrhea have occurred in cases of massive infection and expulsion of worms.

**DOSAGE AND ADMINISTRATION** The same dosage schedule applies to children and adults. The tablet may be chewed, swallowed or crushed and mixed with food. For the control of pinworm (enterobiasis), a single tablet is administered orally, one time. For the control of common roundworm (ascariasis), whipworm (trichuriasis), and hookworm infection, one tablet of VERMOX is administered, orally, morning and evening, on three consecutive days. If the patient is not cured three weeks after treatment, a second course of treatment is advised. No special procedures, such as fasting or purging, are required.

**HOW SUPPLIED** VERMOX is available as chewable tablets, each containing 100 mg of mebendazole, and is supplied in boxes of twelve tablets. VERMOX (mebendazole) is an original product of Janssen Pharmaceutica, Belgium.

US Patent 3,657,267  
December 1979

Committed to research...  
because so much remains to be done.

Tableted by Janssen Pharmaceutica, Beerse, Belgium for



**JANSSEN**  
PHARMACEUTICA

New Brunswick, New Jersey 08903

not mentioned as a finding of thyroiditis in two standard thyroid texts consulted.<sup>5,6</sup> One explanation for this omission is probably that, when thyroid diagnoses are being considered, myopathy draws attention to the hypothyroidism per se rather than the thyroid inflammatory process resulting in the hypofunctional state. This is especially true in the absence of a goiter, which specific finding might more likely provoke thoughts of thyroiditis.

In the patient presented, the diagnosis of primary hypothyroidism was substantiated by the depressed levels of serum T<sub>4</sub> and T<sub>3</sub> and by the elevated TSH. The diagnosis of autoimmune thyroiditis (probably the "atrophic variant"<sup>6</sup>) is supported by the markedly elevated antithyroglobulin antibody level in this clinical setting; Volpé<sup>6</sup> notes that thyroglobulin antibody titers of over 1:20,000 may be found only in chronic lymphocytic (auto-immune) thyroiditis or in Graves' disease.

The diagnosis of myopathy in the absence of a muscle biopsy was supported by the patient's elevated serum CPK and his subjective, focal paresthesias and weakness, severe enough to disturb him in his work with heavy tombstones. (As to the lack of objectively demonstrable weakness on examination, it should be emphasized that the patient was quite muscular and of significantly greater strength than his examiner, so that relatively subtle signs of muscle weakness may have passed unnoticed.)

In summary, the patient discussed presented with thyroiditis and resulting hypothyroidism; apart from laboratory abnormalities, the only indication of his actual endocrine disorder was myasthenic (myopathic) in nature. Furthermore, subjective strength returned and laboratory studies normalized with thyroid hormone treatment alone. It is not known, of course, had treatment not been instigated, when other signs and symptoms of hypothyroidism would have developed; it is presumed his myopathy would have worsened, consistent with findings of the authors cited above.

Thus, myopathic symptoms, as in this patient, may signify a hypothyroid disorder, including thyroiditis, and not only thyroiditis but also myopathy may be the first (and only) nonlaboratory indicator of the dysthyroid state. These facts should be

borne in mind as the primary physician considers the clinical conundrum of thyroid disease and when he or she is called upon to evaluate the patient with myasthenic symptoms.

#### References

1. Fessel WJ: Myopathy of hypothyroidism. *Ann Rheum Dis* 27:590, 1968

2. Graig FA, Smith CJ: Serum creatine phosphokinase activity in altered thyroid states. *J Clin Endocrinol* 25:723, 1965

3. McKeran RO, Slavin G, Ward P, et al: Hypothyroid myopathy: A clinical and pathological study. *J Pathol* 132(1):35, 1980

4. Ingbar SH, Werber KA: In Williams RH (ed): *Textbook of Endocrinology*, ed 6. Philadelphia, WB Saunders, 1981, p 208

5. Pinchera A, Fenzi GF, Bartalena L, et al: The Thyroid Gland, De Visscher M (ed). In Martini L (ed): *Comprehensive Endocrinology series*. New York, Raven Press, 1980, p 433

6. Volpé R: Chronic Thyroiditis. In Werner SC, Ingbar SH (eds): *The Thyroid: A Fundamental Clinical Text*, ed 3. Hagerstown, Md, Harper & Row, 1971, p 868

# A Four-Year Experience with Hemocult Testing Kits in a Family Medicine Center

Sam C. Eggertsen, MD, and James J. Bergman, MD  
Seattle, Washington

The importance of screening for colorectal cancer is widely accepted and has been reviewed in this journal.<sup>1</sup> The Hemocult\* slide test is perhaps the best screening method for colon cancer. It is also used to determine whether gastrointestinal blood loss is occurring in symptomatic patients. This report presents four years of experience using prepared kits given to patients in a family practice clinic.

## Methods

A standardized method of Hemocult screening was introduced in the Family Medical Center at the University of Washington in June 1978. The population served at this residency training site (18 residents, 10 faculty) includes 7,100 patients, most of whom live in the surrounding university community of middle-class predominance. Thirty-two percent of the active registered patients are over the age of 35 years, with a female-to-male ratio of 1 to 6. Forty percent of total patient visits (1982) were from patients over the age of 35 years, with a female-to-male ratio of 2 to 1. The clinic screening protocol for adults over the age of 40 years includes Hemocult testing every one to two years. Kits are prepared that contain three Hemocult cards, applicators, instructions (including a recommended diet), and a return envelope. Attached

From the Department of Family Medicine, University of Washington, Seattle, Washington. Requests for reprints should be addressed to Dr. Sam Eggertsen, Department of Family Medicine, RF-30, School of Medicine, University of Washington, Seattle, WA 98195.

\*SmithKline Diagnostics, Inc, Sunnyvale, California.